Compass Therapeutics (NASDAQ:CMPX) Given Outperform Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research note published on Tuesday,RTT News reports. Wedbush currently has a $8.00 price target on the stock.

CMPX has been the topic of a number of other reports. Piper Sandler initiated coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price target on the stock. Guggenheim began coverage on Compass Therapeutics in a research report on Monday, February 24th. They issued a “buy” rating and a $12.00 target price on the stock. Jefferies Financial Group boosted their price target on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, February 10th. D. Boral Capital reiterated a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.38.

Compass Therapeutics Stock Performance

CMPX opened at $2.24 on Tuesday. The company’s 50-day simple moving average is $2.83 and its two-hundred day simple moving average is $2.11. The stock has a market capitalization of $309.75 million, a P/E ratio of -6.05 and a beta of 1.19. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Research analysts forecast that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers raised its holdings in Compass Therapeutics by 3.1% during the fourth quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock valued at $187,000 after acquiring an additional 3,822 shares during the period. Invesco Ltd. grew its position in shares of Compass Therapeutics by 11.3% during the fourth quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock worth $57,000 after purchasing an additional 4,018 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Compass Therapeutics by 2.6% during the fourth quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock worth $345,000 after purchasing an additional 6,041 shares in the last quarter. ProShare Advisors LLC raised its stake in Compass Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after purchasing an additional 9,451 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Compass Therapeutics by 31.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock worth $69,000 after purchasing an additional 11,326 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.